2013
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
Petrylak D, Kantoff P, Mega A, Vogelzang N, Stephenson J, Fleming M, Stambler N, Petrini M, Huang K, Israel R. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. Journal Of Clinical Oncology 2013, 31: 119-119. DOI: 10.1200/jco.2013.31.6_suppl.119.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerProstate-specific membrane antigenMonomethyl auristatin EFree MMAEProstate cancer cellsProgressive metastatic castration-resistant prostate cancerDose levelsPhase 1 dose-escalation studyLiver function test elevationsCastration-resistant prostate cancerTaxane-containing chemotherapyAntitumor activityDose-escalation studyPhase 2 trialPhase I trialCancer cellsClinical disease progressionHighest dose levelSpecific membrane antigenECOG statusLFT abnormalitiesPrior docetaxelAdverse eventsEscalation studyI trial
2012
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
Mega A, Petrylak D, Kantoff P, Stephenson J, Vogelzang N, Dreicer R, Shore N, Stambler N, Carpenito J, D'Ambrosio P, Israel R. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. Journal Of Clinical Oncology 2012, 30: 4662-4662. DOI: 10.1200/jco.2012.30.15_suppl.4662.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerMonomethyl auristatin EHighest dose levelFree MMAEProstate cancer cellsDose levelsAdverse eventsProgressive metastatic castration-resistant prostate cancerPhase 1 dose-escalation studyCastration-resistant prostate cancerTumor cellsHigh-dose cohortTaxane-containing chemotherapyAntitumor activityCommon laboratory abnormalitiesDose-escalation studyLiver function testsPhase I trialCancer cellsClinical disease progressionDose cohortsECOG statusEscalation studyLaboratory abnormalitiesDose escalation
2009
A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer
Petrylak D, Resto-Garces K, Tibyan M, Mohile S. A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. Journal Of Clinical Oncology 2009, 27: 5156-5156. DOI: 10.1200/jco.2009.27.15_suppl.5156.Peer-Reviewed Original ResearchMeasurable diseaseDay 1Dose levelsPhase I open-label studyCastration-resistant prostate cancerGrade 3 neutropeniaGrade 3/4 toxicitiesGrade 4 neutropeniaMedian baseline PSAOpen-label studyPost-treatment PSAPrior chemotherapy regimensMetastatic pulmonary nodulesDeep venous thrombosisFurther dose escalationPhase I trialEfficacy of docetaxelNear complete resolutionCycle 1Derivative of thalidomideAntiandrogen withdrawalNCI trialProphylactic anticoagulationTreatment PSAChemotherapy regimens